Analysts at Barclays Capital increased their price target on shares of Bristol-Myers Squibb (NYSE:BMY) from $42.00 to $45.00 in a research report issued to clients and investors on Wednesday, StockRatingsNetwork.com reports. The firm currently has an “equal weight” rating on the stock. Barclays Capital’s target price points to a potential upside of 1.10% from the company’s current price.
A number of other firms have also recently commented on BMY. Analysts at Jefferies Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note to investors on Friday, July 12th. They now have a GBX 49 ($0.74) price target on the stock, down previously from GBX 53 ($0.80). Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note to investors on Tuesday, June 18th. They now have a $45.00 price target on the stock. Finally, analysts at UBS AG raised their price target on shares of Bristol-Myers Squibb from $40.00 to $48.00 in a research note to investors on Tuesday, June 11th. They now have a “buy” rating on the stock.
One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Buy” and a consensus price target of $45.58.
Bristol-Myers Squibb (NYSE: BMY) traded down 0.49% on Wednesday, hitting $44.29. Bristol-Myers Squibb has a 52-week low of $30.64 and a 52-week high of $49.57. The stock’s 50-day moving average is currently $45.8. The company has a market cap of $72.749 billion and a price-to-earnings ratio of 50.41.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Thursday, April 25th. The company reported $0.41 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.41. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.88 billion. During the same quarter in the previous year, the company posted $0.64 earnings per share. The company’s revenue for the quarter was down 27.0% on a year-over-year basis. Bristol-Myers Squibb has set its FY13 guidance at $1.78-1.88 EPS. On average, analysts predict that Bristol-Myers Squibb will post $1.81 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 3.15%. The ex-dividend date is Tuesday, July 2nd.
Bristol-Myers Squibb Company (NYSE: BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.